Paul Matteis
Stock Analyst at Stifel
(1.30)
# 3,406
Out of 4,749 analysts
105
Total ratings
35.82%
Success rate
-11.45%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $461.68 | +7.00% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $15.74 | +103.30% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $7.25 | -17.24% | 5 | Dec 16, 2024 | |
| ALEC Alector | Downgrades: Hold | $4 | $1.66 | +140.96% | 4 | Dec 16, 2024 | |
| ANRO Alto Neuroscience | Maintains: Buy | $32 → $10 | $4.29 | +133.10% | 3 | Nov 13, 2024 | |
| NGNE Neurogene | Maintains: Buy | $44 → $60 | $15.85 | +278.55% | 2 | Nov 12, 2024 | |
| ALKS Alkermes | Upgrades: Buy | $25 → $36 | $31.53 | +14.18% | 8 | Nov 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $115 → $87 | $63.36 | +37.31% | 8 | Sep 17, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $41 → $66 | $14.22 | +364.14% | 3 | Aug 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $35 | $16.41 | +113.28% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $31.90 | +66.14% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 → $295 | $271.31 | +8.73% | 13 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $18.66 | +12.54% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $9.79 | +196.22% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $151.82 | -5.15% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $143.93 | +99.40% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.43 | +268.32% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.89 | +315.22% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $1.93 | +1,247.15% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.29 | +1,760.47% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.53 | +851.84% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $8.91 | +259.15% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.38 | +908.40% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.50 | +1,700.00% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $10.60 | +145.28% | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $7.90 | +77.22% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $11.57 | +453.15% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $18.58 | +1,730.42% | 1 | Dec 21, 2016 |
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $461.68
Upside: +7.00%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $15.74
Upside: +103.30%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $7.25
Upside: -17.24%
Alector
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.66
Upside: +140.96%
Alto Neuroscience
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $4.29
Upside: +133.10%
Neurogene
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $15.85
Upside: +278.55%
Alkermes
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $31.53
Upside: +14.18%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $63.36
Upside: +37.31%
Dyne Therapeutics
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $14.22
Upside: +364.14%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $16.41
Upside: +113.28%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $31.90
Upside: +66.14%
Jun 27, 2024
Maintains: Buy
Price Target: $215 → $295
Current: $271.31
Upside: +8.73%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $18.66
Upside: +12.54%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $9.79
Upside: +196.22%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $151.82
Upside: -5.15%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $143.93
Upside: +99.40%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $5.43
Upside: +268.32%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.89
Upside: +315.22%
Oct 10, 2023
Initiates: Buy
Price Target: $26
Current: $1.93
Upside: +1,247.15%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.29
Upside: +1,760.47%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.53
Upside: +851.84%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $8.91
Upside: +259.15%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $2.38
Upside: +908.40%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.50
Upside: +1,700.00%
Jul 20, 2021
Initiates: Buy
Price Target: $26
Current: $10.60
Upside: +145.28%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $7.90
Upside: +77.22%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $11.57
Upside: +453.15%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $18.58
Upside: +1,730.42%